Japanese Journal of Clinical Oncology 31:424-427 (2001)
© 2001 Foundation for Promotion of Cancer Research
Effects of Tamoxifen on the Serum Leptin Level in Patients with Breast Cancer
Departments of 1Medical Oncology and 2Epidemiology, Gulhane School of Medicine, Etlik, Ankara, Turkey
Background: Leptin is a peptide hormone that has a role in the regulation of body weight and has effects on metabolic, neuroendocrine, reproductive and hematopoietic systems. Breast cancer has also been associated with obesity and reproductive hormones, especially estradiol. Only a few studies have investigated the relation between plasma leptin and risk of breast cancer and only one study evaluated the effect of tamoxifen on leptin levels in patients with breast cancer.
Methods: We investigated serum leptin levels in gender-, body mass index (BMI)- and age-matched breast cancer patients and healthy individuals (58 of each).
Results: Serum leptin levels were measured by radioimmunoassay (Human Leptin RIA Kit). Serum leptin levels in the breast cancer patients were significantly higher than those in the control group (27.00 versus 17.65 ng/ml, p = 0.019). There were no differences with respect to BMI and age between control and breast cancer patients. There were no significant differences in BMI and leptin levels between pre- and postmenopausal patients (27.00 ± 1.39 and 27.19 ± 0.81 kg/m2, 26.81 ± 6.25 and 27.06 ± 2.98 ng/ml) (p > 0.05). We found no difference in serum leptin level between early and late stages of patients (22.38 versus 31.30 ng/ml, p = 0.086). However, the serum leptin level in patients using tamoxifen was significantly higher than that of patients not using tamoxifen (32.71 and 19.39 ng/ml, respectively p = 0.009). There was no correlation between CA 15-3 and leptin level (r = 0.069, p = 0.610).
Conclusion: High serum leptin levels seen in breast cancer patients are not related to stage of the disease or to cancer itself but may be associated with the use of tamoxifen.
+ For reprints and all correspondence: Ahmet Ozet, Department of Medical Oncology, Gulhane School of Medicine, 06018 Etlik, Ankara, Turkey. E-mail: aozet@gata.edu.tr
Abbreviations: ER, estrogen receptor; p, positive; n, negative; u, unknown; BMI, body mass index; T+, receiving tamoxifen; T–, not receiving tamoxifen; C, receiving chemotherapy; SEM, standard error of the mean
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. K. Neilson, C. M. Friedenreich, N. T. Brockton, and R. C. Millikan Physical Activity and Postmenopausal Breast Cancer: Proposed Biologic Mechanisms and Areas for Future Research Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 11 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Vona-Davis and D. P Rose Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression Endocr. Relat. Cancer, June 1, 2007; 14(2): 189 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Demirkan, A. Alacacioglu, and U. Yilmaz Relation of Body Mass Index (BMI) to Disease Free (DFS) and Distant Disease Free Survivals (DDFS) Among Turkish Women with Operable Breast Carcinoma Jpn. J. Clin. Oncol., April 1, 2007; 37(4): 256 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Goodwin, M. Ennis, I. G. Fantus, K. I. Pritchard, M. E. Trudeau, J. Koo, and N. Hood Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer? J. Clin. Oncol., September 1, 2005; 23(25): 6037 - 6042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]
|
|
|
|
|
|
L Hilakivi-Clarke, C Wang, M Kalil, R Riggins, and R G Pestell Nutritional modulation of the cell cycle and breast cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 603 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ishikawa, J. Kitayama, and H. Nagawa Enhanced Expression of Leptin and Leptin Receptor (OB-R) in Human Breast Cancer Clin. Cancer Res., July 1, 2004; 10(13): 4325 - 4331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Eng-Wong, S. D. Hursting, D. Venzon, S. N. Perkins, and J. A. Zujewski Effect of Raloxifene on Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Leptin in Premenopausal Women at High Risk for Developing Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1468 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Catalano, S. Marsico, C. Giordano, L. Mauro, P. Rizza, M. L. Panno, and S. Ando Leptin Enhances, via AP-1, Expression of Aromatase in the MCF-7 Cell Line J. Biol. Chem., August 1, 2003; 278(31): 28668 - 28676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Poirier and L. J. Schild The Genotoxicity of Tamoxifen: Extent and Consequences, Kona, Hawaii, January 23, 2003 Mutagenesis, July 1, 2003; 18(4): 395 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Hu, S. C. Juneja, N. J. Maihle, and M. P. Cleary Leptin--A Growth Factor in Normal and Malignant Breast Cells and for Normal Mammary Gland Development J Natl Cancer Inst, November 20, 2002; 94(22): 1704 - 1711. [Abstract] [Full Text] [PDF]
|
|